Clinical bottom line
Bispecific antibodies, particularly blinatumomab, represent a significant advancement in the treatment of acute lymphoblastic leukemia (ALL), offering improved remission rates and survival compared to conventional chemotherapy, especially in relapsed or refractory disease. Recent studies demonstrate that subcutaneous administration of blinatumomab is feasible and effective, potentially enhancing patient convenience and tolerability. While pediatric ALL treatment continues to evolve with novel immunotherapies, bispecific antibodies are increasingly integrated into frontline and salvage regimens. However, challenges remain regarding optimal sequencing, toxicity management, and long-term outcomes (Kantarjian et al., 2017; Jabbour et al., 2024; Lussana et al., 2021).
What the evidence shows
Kantarjian et al. (2017) conducted a pivotal randomized trial comparing blinatumomab to standard chemotherapy in adults with relapsed or refractory ALL, demonstrating superior overall survival (median 7.7 vs. 4.0 months) and higher complete remission rates with blinatumomab. This study established blinatumomab as a new standard in this setting.
Jabbour et al. (2024) report on a phase II trial evaluating subcutaneous blinatumomab in advanced ALL, showing comparable efficacy to intravenous administration with a favorable safety profile, suggesting a more convenient delivery method that may improve outpatient management.
Lussana et al. (2021) review T cell–redirected bispecific antibodies in ALL and lymphoma, highlighting their mechanism of action, clinical efficacy, and emerging agents beyond blinatumomab. They discuss the potential of bispecific antibodies to overcome resistance and reduce reliance on intensive chemotherapy.
Inaba et al. (2020) and Marrapodi et al. (2025) provide comprehensive overviews of pediatric ALL treatment, noting that bispecific antibodies are increasingly incorporated into pediatric protocols, improving outcomes while potentially reducing chemotherapy-related toxicity.
Caveats and uncertainty
Most bispecific antibody data derive from relapsed/refractory populations; evidence in frontline therapy is still emerging.
Cytokine release syndrome and neurotoxicity remain significant adverse events requiring careful monitoring and management.
Long-term durability of responses and impact on quality of life require further study.
Optimal integration with other immunotherapies, such as CAR T-cell therapy, is not yet defined.
Pediatric data, while promising, are less mature than adult studies.
How this may change practice
Clinicians should consider bispecific antibodies like blinatumomab for patients with relapsed/refractory ALL to improve remission rates and survival.
Subcutaneous blinatumomab may facilitate outpatient administration, enhancing patient convenience and resource utilization.
Early incorporation of bispecific antibodies in pediatric and adult frontline regimens may reduce chemotherapy intensity and toxicity.
Multidisciplinary teams must be prepared to manage immune-related adverse events associated with these agents.
Ongoing clinical trials and real-world data will inform optimal sequencing and combination strategies.